Upstream Bio Presented Results From The Phase 2 VALIANT Clinical Trial Evaluating The Safety And Efficacy Of Verekitug In Adults With Severe Asthma In A Late-breaking Oral Presentation At The European Respiratory Society Congress 2026 In Barcelona

Loading news article.

Upstream Bio Presented Results From The Phase 2 VALIANT Clinical Trial Evaluating The Safety And Efficacy Of Verekitug In Adults With Severe Asthma In A Late-breaking Oral Presentation At The European Respiratory Society Congress 2026 In Barcelona | WAPE

Upstream Bio Presented Results From The Phase 2 VALIANT Clinical Trial Evaluating The Safety And Efficacy Of Verekitug In Adults With Severe Asthma In A Late-breaking Oral Presentation At The European Respiratory Society Congress 2026 In Barcelona

Article summary

Related companies

Comments —